Patients on atypical antipsychotic drugs: Another high-risk group for type 2 diabetes

Diabetes Care

Volumn 26, Issue 5, 2003, Pages 1597-1605

  Lean, Michael E J ^a   Pajonk, Frank Gerald ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CLOZAPINE; GLUCOSE; INSULIN; LEPTIN; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 1 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; ZIPRASIDONE;

CARDIOVASCULAR RISK; DIABETIC KETOACIDOSIS; DIET; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT PLANNING; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; RISK FACTORS; SCHIZOPHRENIA;

EID: 0038220770     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.5.1597     Document Type: Review

References (84)

1. Brown S: Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 171:502-508, 2001
2. Axelsson R, Lagerkvist-Briggs M: Factors predicting suicide in psychotic patients. Eur Arch Psychiatr Clin Neurosci 241:259-266, 1992
3. Cohen LJ, Test MA, Brown RL: Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry 147:602-607, 1990
4. Mortensen PB, Juel K: Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 163:183-189, 1993
5. Davies LM, Drummond MF: The economic burden of schizophrenia. Psychiatr Bull 14:522-525, 1990
6. Rupp A, Keith SJ: The cost of schizophrenia. Psychiatr Clin North Am 16:413-423, 1993
7. Seeman P, Chau-Wong M, Wong K: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717-719, 1976
8. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38, 2002
9. Adams PF, Marano MA: Current estimates from the National Health Interview Survey [article online], 1994. Available from http://www.cdc.gov/nchs/data/series/sr_10/sr10_193acc.pdf
10. Bhide M, Tiwari N, Balwani J: Effect of chlorpromazine on peripheral utilization of glucose. Arch Int Pharmacodyn 156:166-171, 1965
11. Charatan FBE, Bartlett NG: The effect of chlorpromazine ("Largactil") on glucose tolerance. J Mental Sci 191:351-353, 1955
12. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A: Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903-912, 2000
13. Dynes JB: Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Syst 30:341-344, 1969
14. Hiles B: Hyperglycaemia and glycosuria following chlorpromazine therapy (Letter). J Am Med Assoc 162:1651, 1956
15. McKee HA, D'Arcy PF, Wilson PJ: Diabetes and schizophrenia: a preliminary study. J Clin Hosp Pharm 11:297-299, 1986
16. Newcomer JW, Craft S, Fucetola R, Moldin SO, Selke G, Para L, Miller R: Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull 25:321-335, 1999
17. Thonnard-Neumann E: Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 124:978-982, 1968
18. Waitzkin LA: A survey for unknown diabetes in a mental hospital. Diabetes 15:164-172, 1966
19. Benson V, Marano MA: Current estimates from the National Health Interview Survey [article online], 1995. Available from http://www.cdc.gov/nchs/data/series/sr_10/sr10_199acc.pdf
20. Braceland FJ, Meduna LJ, Vaichulis JA: Delayed action of insulin in schizophrenia. Am J Psychiatry 102:108-110, 1945
21. Freeman H: Resistance to insulin in mentally disturbed soldiers. Arch Neurol Psychiatry 56:74-78, 1946
22. Harris MI: Impaired glucose tolerance in the U.S. population. Diabetes Care 12:464-474, 1989
23. Kasanin J: The blood sugar curve in mental disease. Arch Neurol Psychiatry 16:414-419, 1926
24. Langfeldt G: The insulin tolerance test in mental disorders. Acta Psychiatr Scand 80:189-200, 1952
25. Lorenz WF: Sugar tolerance in dementia praecox and other mental isorders. Arch Neurol Psychiatry 8:184-196, 1922
26. Mukherjee S, Schnur DB, Reddy R: Family history of type 2 diabetes in schizophrenic patients (Letter). Lancet 1:495, 1989
27. Semyak MJ, Douglas DL, Alarcon RD, Losonczy MF, Rosenheck R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159:561-566, 2002
28. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little R, Wiedermeyer H, Byrd-Holt D: Prevalence of diabetes, impaired fasting glucose tolerance in US adults: the Third National Health and Nutrition Examination Survey. Diabetes Care 21:518-524, 1998
29. Liebzeit KA, Markowitz JS, Caley CF: New onset diabetes and atypical antipsychotics. European Neuropsychopharmacology 11:25-32, 2001
30. Mir S, Taylor D: Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 16:63-74, 2001
31. Muensch J, Carey M: Diabetes mellitus associated with atypical antipsycholic medications: new case report and review of the literature. J Am Board Fam Pract 14:278-282, 2001
32. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC: Novel antipsychotics and new onset diabetes. Biol Psychiatry 44:778-783, 1998
33. Bonanno DG, Davydov L, Botts SR: Olanzapine-induced diabetes mellitus. Ann Pharmacother 35:563-565, 2001
34. Brugman NJ, Cohen D, De Vries RH: Diabetese mellitus ontstaan na behandeling met clozapine. Ned Tijdschr Geneeskd 144:437-439, 2000
35. Croarkin PE, Jacobs KM, Bain BK: Diabetic ketoacidosis associated with risperidone treatment? (Letter) Psychosomatics 41:369-370, 2000
36. Procyshyn RM, Pande S, Tse G: New-onset diabetes mellitus associated with quetiapine. Can J Psychiatry 45:668-669, 2000
37. Rigalleau V, Gatta B, Bonnaud S, Bourgeois ML, Vergnot V, Gin H: Diabetes as a result of atypical antipsychotic drugs: a report of three cases. Diabet Med 17:484-486, 2000
38. Roefaro J, Mukherjee SM: Olanzapine-induced hyperglycaemic nonketotic coma. Ann Pharmacother 35:300-302, 2001
39. Selva KA, Scott SM: Diabetic ketoacidosis associated with olanzapine in an adolescent patient. J Pediatr 138:936-938, 2001
40. Smith H, Kenney-Herbert J, Knowles L: Clozapine-induced diabetic ketoacidosis. Aust N Z J Psychiatry 120-121, 1999
41. Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC: Risperidone-associated new-onset diabetes. Biol Psychiatry 50:148-149, 2001
42. Wu G, Dias P, Wu C, Li G-J, Kumar S, Singh S: Hyperglycemia, hyperlipidaemia and periodic paralysis: a case report of new side effects of clozapine. Prog Neuro-Psychopharmacol Biol Psychiatry 24:1395-1400, 2000
43. Koller EA, Schneider B, Bennett K, Dubitsky G: Clozapine-associated diabetes. Am J Med 111:716-723, 2001
44. Koller EA, Doraiswamy PM: Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841-852, 2002
45. Mahmoud R, Gianfrancesco F, Grogg A, Nasrallah HA: Differential effects of antipsychotics on type 2 diabetes: findings from a large health plan database. In Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, Dec. 10-14, 2001, p. 199
46. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC: Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975-981, 2000
47. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J: Clozapine use and risk of diabetes mellilus. J Clin Psychopharmacol 22:236-243, 2002
48. Berry SA, Mahmoud RA: Normalization of olanzapine-associated abnormalities of insulin resistance and insulin release after switch to risperidone: the Risperidone Rescue Study (Poster). Presented at the American College of Neuropsychopharmacology meeting, Hawaii, December, 2001
49. IMS Health National Prescription Audit Plus, 2001
50. Chue P, Welch R: Investigation of the metabolic effects of antipsychotics in patients with schizophrenia (Poster). Presented at the 51st Annual Meeting of the Canadian Psychiatric Association, Quebec, October-November 2001
51. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyerbuhl J, Revicki DA, Buchanan RW: Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 325:243-245, 2002
52. Czobor P, Volavka J, Sheitman B, Lindenmeyer J-P, Citrome L, McEvoy J, Cooper TB, Chakos M, Lieberman JA: Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacoll 22:244-251, 2002
53. Meyer JM: Effects of atypical antipsychotics on weight gain and serum lipid levels. J Clin Psychiatry 62:27-34, 2001
54. Harris MI: Prevalence of cardiovascular risk factors at the diagnosis of type 2 diabetes. Clin Invest Med 18:231-239, 1995
55. Pi-Sunyer FX: Medical hazards of obesity. Ann Intern Med 119:655-660, 1993
56. UKPDS Study Group: Characteristics of newly presenting type 2 diabetic patients: male preponderance and obesity at different ages. Diabet Med 5:154-159, 1998
57. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156:1686-1696, 1999
58. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR: Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 60:358-363, 1999
59. Wirshing DA: Adverse effects of atypical antipsychotics. J Clin Psychiatry 62:7-10, 2001
60. Cohen D: Atypical antipsychotics and new-onset diabetes mellitus: an overview of the literature. Pharmacopsychiatry. In press
61. Cagliero E, Borba CP, Hayden DL, Schoenfeld DA, Goff DG, Henderson DC: Clozapine and olanzapine induce insulin resistance in patients with schizophrenic disorders (Abstract). Diabetes 50 (Suppl. 2):A91, 2001
62. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G: Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59:337-345, 2002
63. Leysen JE, Janssen PMF, Hellen L, Gommeren W, Van Gomple P, Lesage AS, Megens AAHP, Schotte A: Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects. Int J Psychiatry Clin Pract 2:S3-S17, 1998
64. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D: Eating disorders and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 374:542-546, 1995
65. 2 receptor agonist DOI and α-methyl-5-HT on plasma glucose and insulin levels in the rat. Eur J Pharmacol 187:435- 443, 1990
66. Baudrie V, Chaouloff F: Repeated treatment with the 5-HT1A receptor agonist, isapirone, does not affect 8-OH-DPAT- and stress-induced increases in plasma adrenaline levels in the rat. Eur J Pharmacol 198:129-135, 1991
67. Sugimoto Y, Yamada J, Kimura I, Horiska K: The effects of the serotonin 1A receptor agonist buspirone on tolbutamide-induced hypoglycemia in rats. Biol Pharm Bull 18:1296-1298, 1995
68. Uvnas-Moberg K, Ahlenius S, Alster P, Hillegaart V: Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin, and glucagon in the rat. Neuroendocrinology 63:269-274, 1996
69. Wozniak KM, Linnoila M: Hyperglycemic properties of serotonin receptor antagonists. Life Sci 49:101-109, 1991
70. Goldstein LE, Spom J, Brown S, Kim H, Finkelstein J, Gaffey GK, Sachs G, Stern TA: New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438-443, 1999
71. Melkersson KI, Hulting AL, Brismar KE: Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 61:742-749, 2000
72. Meyer JM: Antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21:369-374, 2001
73. Dwyer DS, Pinkofsky HB, Liu Y, Bradley RJ: Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC12 cells. Prog Neuro-Psychopharmacol Biol Psychiatry 23:69-80, 1999
74. Bromel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand J: Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 3:76-80, 1998
75. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kuhn M, Uhr M, Pollmacher T: Body weight gain and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156:312-314, 1999
76. Melkersson KI, Hulting AL, Brismar KE: Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry 60:783-791, 1999
77. Woods SC, Kaiyala K, Porte D, Schwartz MW: Food intake and energy balance. In Diabetes Mellitus. Porte D, Sherwin RS, Eds. Stamford, CT, Appleton & Lange, 1997, p. 175-192
78. Herrán A, Garcia-Unzueta MT, Amado JA, de la Maza MT, Álvarez C, Vázquez-Barquero JL: Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry 179:59-62, 2001
79. Davis JM, Andriukutis S: The natural course of schizophrenia and effective maintenance therapy. J Clin Psychopharmacol 6:2-10, 1986
80. Csernansky JG, Mahmoud R, Brenner R, for the Risperidone-USA-79 Study Group: A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16-22, 2002
81. Burns MJ: The pharmacology and toxicology of atypical antipsychotic agents. Clin Toxicol 39:1-14, 2001
82. Ereshefsky L: Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 57:12-15, 2002
83. Indiana University Department of Medicine Cytochrome P450 Drug Interaction Table [article online], 2003. Available from http://medicine.iupui.edu/flockhart/. Accessed 2 July 2002
84. Neaton JD, Wentworth D: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease: overall findings and differences by age for 316,099 white men: Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 152:56-64, 1992